ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

LIAN LianBio

0,319
0,00 (0,00%)
09 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
LianBio LIAN NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
0,00 0,00% 0,319 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,319 0,319
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
11/3/202412:51EDGAR2Form 25 - Notification of the removal from listing and..
28/2/202413:00GLOBELianBio Announces Voluntarily Delisting from Nasdaq
20/2/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202413:04EDGAR2Form 8-K - Current report
13/2/202413:00GLOBELianBio Announces Completion of Strategic Review
08/1/202412:13EDGAR2Form 144 - Report of proposed sale of securities
29/12/202313:56EDGAR2Form 144 - Report of proposed sale of securities
26/12/202322:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/12/202322:07EDGAR2Form 8-K - Current report
26/12/202320:40APSBiotech Finds Success Following Holiday Weekend
26/12/202308:00GLOBELianBio Enters into Agreement Assigning its Rights for..
20/12/202314:05EDGAR2Form 8-K - Current report
20/12/202314:00GLOBELianBio Announces Departure of Chief Financial Officer
19/12/202322:26EDGAR2Form 8-K - Current report
19/12/202322:05GLOBELianBio Announces Departure of Chief Executive Officer
06/12/202322:23EDGAR2Form 8-K - Current report
06/12/202322:05GLOBELianBio’s Board of Directors Unanimously Determines not to..
01/12/202322:16EDGAR2Form 8-K - Current report
01/12/202322:05GLOBELianBio Confirms Receipt of Unsolicited Proposal from..
13/11/202322:28EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:17EDGAR2Form 8-K - Current report
13/11/202322:05GLOBELianBio Reports Third Quarter 2023 Financial Results and..
30/10/202321:16EDGAR2Form 8-K - Current report
30/10/202321:05GLOBELianBio Announces Topline Results from Phase 3 LIBRA Trial..
25/10/202322:05GLOBELianBio Announces Presentation of Data from Phase 2a Study..
24/10/202316:25APSBiotech Shares Soar Premarket
24/10/202315:22DJNLianBio Shares Soar Premarket on Strategic Review, End of..
24/10/202312:59GLOBELianBio Enters into Agreement with Bristol Myers Squibb for..
28/8/202322:05GLOBELianBio Announces Results from Phase 3 EXPLORER-CN Trial of..
14/8/202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202322:11EDGAR2Form 8-K - Current report
14/8/202322:05GLOBELianBio Reports Second Quarter 2023 Financial Results and..
03/8/202322:05GLOBELianBio Announces First Patient Treated in Phase 1 Trial of..
26/7/202314:30GLOBELianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA..
18/7/202314:00GLOBELianBio Partner NANOBIOTIX Enters into License Agreement..
17/7/202312:00GLOBELianBio Announces Phase 3 EXPLORER-CN Data Accepted for..
12/7/202314:00GLOBELianBio Announces Clinical Supply Agreement with AstraZeneca..
26/6/202314:00GLOBELianBio Announces Marketing Approval of CAMZYOS®..
08/6/202313:00GLOBELianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial..
08/6/202300:21DJNADRs End Mostly Lower, Oatly and LianBio Trade Actively
06/6/202322:05GLOBELianBio Announces Topline Results from Phase 2a Proof of..
01/6/202322:15GLOBELianBio to Participate in Upcoming Investor Conferences
11/5/202322:15GLOBELianBio Reports First Quarter 2023 Financial Results and..
11/5/202313:00GLOBELianBio Announces Marketing Approval of CAMZYOS®..

Dernières Valeurs Consultées

Delayed Upgrade Clock